Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma (Study 2)

ID Number 08-0395-00004

Principal Investigator(s)
Philip Friedlander

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is:

• Find out what effects, good and/or bad, the combination of dasatinib and bevacizumab have on you and your cancer.

• Find out if the combination of dasatinib and bevacizumab can help you get better.

• Find out if there are individual differences and/or tumor characteristics that will affect response to treatment.

The combination of dasatinib and bevacizumab in this study is considered investigational.

You may qualify to take part in this research study because you have recurrent glioblastoma multiforme. Glioblastoma multiforme is a kind of brain tumor that grows quickly. It usually occurs in adults and is the most common form of brain cancer.

Contact Information
(212) 824-7308
(212) 824-7293

Recruiting Patients: No